Search
Search Results
-
Modulating P-glycoprotein Regulation as a Therapeutic Strategy for Pharmacoresistant Epilepsy
Experimental data suggest a role of blood–brain barrier P-glycoproteinP-glycoprotein (P-gp) overexpression as a factor contributing to drug-resistant...
-
Rifabutin but not rifampicin can partly out-balance P-glycoprotein induction by concurrent P-glycoprotein inhibition through high affinity binding to the inhibitory site
Physiology-based pharmacokinetic modeling suggests that rifabutin can out-balance P-glycoprotein (P-gp) induction by concurrent P-gp inhibition....
-
Cepharanthine synergistically promotes methylprednisolone pharmacodynamics against human peripheral blood mononuclear cells possibly via regulation of P-glycoprotein/glucocorticoid receptor translocation
BackgroundCepharanthin ® alone or in combination with glucocorticoid (GC) has been used to treat chronic immune thrombocytopenia (ITP) since the...
-
Functioning of P-Glycoprotein during Pregnancy in Rabbits
The level P-glycoprotein (Pgp) in organs of pregnant rabbits and its content and activity in the placental barrier at different stages of pregnancy...
-
Quercetin Simultaneously Inhibited Cytochrome P450 and P-Glycoprotein to Improve the Pharmacokinetics of Osthole in Rat Plasma
Plant-based medicines derived from traditional Chinese medicine have garnered widespread attention for their potential in the prevention and...
-
Structure-based discovery of novel P-glycoprotein inhibitors targeting the nucleotide binding domains
P-glycoprotein (P-gp), a membrane transport protein overexpressed in certain drug-resistant cancer cells, has been the target of numerous drug...
-
Novel betulin derivatives as multidrug reversal agents targeting P-glycoprotein
Chemotherapy is a powerful means of cancer treatment but its efficacy is compromised by the emergence of multidrug resistance (MDR), mainly linked to...
-
Elucidating the Inhibition Mechanism of FDA-Approved Drugs on P-glycoprotein (P-gp) Transporter by Molecular Docking Simulation
P-glycoprotein (MDR1) is an efflux transporter that regulates the elimination of the substrates, drugs, and drug metabolites from the liver into the...
-
Essential role of P-glycoprotein in the mechanism of action of oliceridine
Mu opioid receptor (MOR) agonists comprise the most effective analgesics, but their therapeutic utility is limited by adverse effects. One approach...
-
-
Investigating Natural Inhibitors of Permeability-Glycoprotein (P-gp) Liver Transporter via Molecular Docking Simulation for Hepatocellular Carcinoma Therapy
Permeability-glycoprotein (P-gp), a dynamic efflux pump responsible for transporting xenobiotics and drugs out of cells, is a contributor to...
-
Assessment of Malondialdehyde Belonging to Modulators and Substrates of the P-Glycoprotein Transporter Protein
AbstractIn the study on cells of the Caco-2 line, the affiliation of malondialdehyde (MDA) to modulators and substrates of P-glycoprotein (Pgp) was...
-
Mechanisms of Testosterone Effects on the Transport Protein P-Glycoprotein
AbstractP-glycoprotein (Pgp) is an efflux membrane transport protein that plays an important role in the protection of tumor cells from cytostatics...
-
Anti-high mobility group box protein 1 monoclonal antibody downregulating P-glycoprotein as novel epilepsy therapeutics
Epilepsy, a neurological illness, is characterized by recurrent uncontrolled seizures. There are many treatments of options that can be used as the...
-
Monitoring Multidrug Resistance P-Glycoprotein Drug Transport Activity with Single-Photon Emission Computed Tomography and Positron Emission Tomography Radiopharmaceuticals
Multidrug resistance (MDR) mediated by overexpression of MDR1 P-glycoprotein (Pgp) is one of the best characterized transporter-mediated barriers to...
-
Effect of Nitric Oxide on the Functioning of the P-Glycoprotein Transporter
We studied the effect of nitric oxide (NO) on the functioning of P-glycoprotein transporter (Pgp) in Caco-2 cells. NO donor S-nitrosoglutathione...
-
Ivermectin Toxicokinetics in Rainbow Trout (Oncorhynchus mykiss) following P-glycoprotein Induction
Alterations in ivermectin (IVM, 22,23-dihydro avermectin B1a+22,23-dihydro avermectin B1b) toxicokinetics following P-glycoprotein (P-gp) induction...
-
Naringenin alters the pharmacokinetics of ranolazine in part through the inhibition of cytochrome P450 (3A4) and P-glycoprotein
BackgroundThis study set out to look at how naringenin affected the pharmacokinetics of ranolazine in rats. The pharmacokinetic investigation of...
-
BI-2865, a pan-KRAS inhibitor, reverses the P-glycoprotein induced multidrug resistance in vitro and in vivo
BackgroundMultidrug resistance (MDR) limits successful cancer chemotherapy. P-glycoprotein (P-gp), BCRP and MRP1 are the key triggers of MDR....
-
Effect of Daridorexant on the Pharmacokinetics of P-Glycoprotein Substrate Dabigatran Etexilate and Breast Cancer Resistance Protein Substrate Rosuvastatin in Healthy Subjects
Background and ObjectiveThe dual orexin receptor antagonist daridorexant was approved in 2022 for the treatment of insomnia at doses up to 50 mg once...
